62 related articles for article (PubMed ID: 15714989)
1. [Novel molecular targeting therapeutics for prostate cancer].
Uemura H; Nakaigawa N; Ishiguro H; Kubota Y
Nihon Rinsho; 2005 Feb; 63(2):339-44. PubMed ID: 15714989
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II up-regulates PAX2 oncogene expression and activity in prostate cancer via the angiotensin II type I receptor.
Bose SK; Gibson W; Giri S; Nath N; Donald CD
Prostate; 2009 Sep; 69(12):1334-42. PubMed ID: 19517575
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment.
Uemura H; Ishiguro H; Kubota Y
Int J Urol; 2008 Jan; 15(1):19-26. PubMed ID: 18184167
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor.
Uemura H; Ishiguro H; Nakaigawa N; Nagashima Y; Miyoshi Y; Fujinami K; Sakaguchi A; Kubota Y
Mol Cancer Ther; 2003 Nov; 2(11):1139-47. PubMed ID: 14617787
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer.
Uemura H; Nakaigawa N; Ishiguro H; Kubota Y
Curr Cancer Drug Targets; 2005 Aug; 5(5):307-23. PubMed ID: 16101380
[TBL] [Abstract][Full Text] [Related]
6. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells.
Lee SO; Lou W; Qureshi KM; Mehraein-Ghomi F; Trump DL; Gao AC
Prostate; 2004 Sep; 60(4):303-9. PubMed ID: 15264241
[TBL] [Abstract][Full Text] [Related]
7. [Role of renin-angiotensin system in prostate cancer].
Uemura H; Kubota Y
Gan To Kagaku Ryoho; 2009 Aug; 36(8):1228-33. PubMed ID: 19692759
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of angiotensin II in modulating cardiac function: intracardiac effects and signal transduction pathways.
Dostal DE; Hunt RA; Kule CE; Bhat GJ; Karoor V; McWhinney CD; Baker KM
J Mol Cell Cardiol; 1997 Nov; 29(11):2893-902. PubMed ID: 9405164
[TBL] [Abstract][Full Text] [Related]
9. Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer.
Kosaka T; Miyajima A; Shirotake S; Kikuchi E; Hasegawa M; Mikami S; Oya M
Prostate; 2010 Feb; 70(2):162-9. PubMed ID: 19760626
[TBL] [Abstract][Full Text] [Related]
10. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells.
Mora LB; Buettner R; Seigne J; Diaz J; Ahmad N; Garcia R; Bowman T; Falcone R; Fairclough R; Cantor A; Muro-Cacho C; Livingston S; Karras J; Pow-Sang J; Jove R
Cancer Res; 2002 Nov; 62(22):6659-66. PubMed ID: 12438264
[TBL] [Abstract][Full Text] [Related]
11. Functional angiotensin II type 2 receptors inhibit growth factor signaling in LNCaP and PC3 prostate cancer cell lines.
Chow L; Rezmann L; Imamura K; Wang L; Catt K; Tikellis C; Louis WJ; Frauman AG; Louis SN
Prostate; 2008 May; 68(6):651-60. PubMed ID: 18288685
[TBL] [Abstract][Full Text] [Related]
12. [Application of angiotensin II receptor blocker in prostate cancer].
Uemura H; Kubota Y
Nihon Rinsho; 2009 Apr; 67(4):807-11. PubMed ID: 19348246
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells.
Ni Z; Lou W; Leman ES; Gao AC
Cancer Res; 2000 Mar; 60(5):1225-8. PubMed ID: 10728680
[TBL] [Abstract][Full Text] [Related]
14. Transactivation of ErbB1 and ErbB2 receptors by angiotensin II in normal human prostate stromal cells.
Lin J; Freeman MR
Prostate; 2003 Jan; 54(1):1-7. PubMed ID: 12481249
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells.
Uemura H; Ishiguro H; Nagashima Y; Sasaki T; Nakaigawa N; Hasumi H; Kato S; Kubota Y
Mol Cancer Ther; 2005 Nov; 4(11):1699-709. PubMed ID: 16275991
[TBL] [Abstract][Full Text] [Related]
16. ErbB kinases and NDF signaling in human prostate cancer cells.
Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
[TBL] [Abstract][Full Text] [Related]
17. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis.
Jing N; Li Y; Xiong W; Sha W; Jing L; Tweardy DJ
Cancer Res; 2004 Sep; 64(18):6603-9. PubMed ID: 15374974
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo.
Gao L; Zhang L; Hu J; Li F; Shao Y; Zhao D; Kalvakolanu DV; Kopecko DJ; Zhao X; Xu DQ
Clin Cancer Res; 2005 Sep; 11(17):6333-41. PubMed ID: 16144938
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines.
Putz T; Culig Z; Eder IE; Nessler-Menardi C; Bartsch G; Grunicke H; Uberall F; Klocker H
Cancer Res; 1999 Jan; 59(1):227-33. PubMed ID: 9892211
[TBL] [Abstract][Full Text] [Related]
20. Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons.
Nagano K; Masters JR; Akpan A; Yang A; Corless S; Wood C; Hastie C; Zvelebil M; Cramer R; Naaby-Hansen S
Oncogene; 2004 Mar; 23(9):1693-703. PubMed ID: 14647428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
